Last reviewed · How we verify
Experimental: CD07223 1.5 % Topical Gel BID
Experimental: CD07223 1.5 % Topical Gel BID is a Small molecule drug developed by NovaBay Pharmaceuticals, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | Experimental: CD07223 1.5 % Topical Gel BID |
|---|---|
| Sponsor | NovaBay Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental: CD07223 1.5 % Topical Gel BID CI brief — competitive landscape report
- Experimental: CD07223 1.5 % Topical Gel BID updates RSS · CI watch RSS
- NovaBay Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Experimental: CD07223 1.5 % Topical Gel BID
What is Experimental: CD07223 1.5 % Topical Gel BID?
Experimental: CD07223 1.5 % Topical Gel BID is a Small molecule drug developed by NovaBay Pharmaceuticals, Inc..
Who makes Experimental: CD07223 1.5 % Topical Gel BID?
Experimental: CD07223 1.5 % Topical Gel BID is developed by NovaBay Pharmaceuticals, Inc. (see full NovaBay Pharmaceuticals, Inc. pipeline at /company/novabay-pharmaceuticals-inc).
What development phase is Experimental: CD07223 1.5 % Topical Gel BID in?
Experimental: CD07223 1.5 % Topical Gel BID is in Phase 2.